Difference between revisions of "Timeline of kidney cancer"

This is a '''timeline of [[kidney cancer]]''', describing especially major discoveries and advances in treatment of the disease.

|19th century||First descriptions of renal carcinoma are recorded. [[Nephrectomy]] is developed.

|20th century||More types of kidney cancers are described. [[Nephrology]] is established in the second half of the century.  

|Prior to 1980s||Very limited alternatives are available to treat [[kidney cancer]]. For patients whose cancer has not spread beyond the [[kidneys]], complete surgical removal of the kidney is often, but not always, effective. For those with more advanced disease, however, the available [[chemotherapy]] and [[radiation]] treatments have little effect and survival is usually limited to a few months.<ref name="Cancer progress" />

|1980s onward||New imaging modalities such as [[ultrasonography]], [[CT scan|computed tomography]], and [[magnetic resonance imaging]] come into widespread use.  

|1990s||[[Immunotherapy]] is introduced, which enables doctors to extend the lives of some patients whose cancer have spread.<ref name="Cancer progress" />

|Present time||Currently, most cases of [[kidney cancer]] occur in the [[developed world]], with the highest incidence in [[North America]] and [[Europe]], and the lowest incidence in Africa and Asia.<ref name="Kidney cancer statistics" />  Treatments today include [[surgery]], [[ablation]], active surveillance, [[radiation therapy]], [[targeted therapy]], [[immunotherapy]] and [[chemotherapy]].<ref>{{cite web|title=How is kidney cancer treated?|url=http://www.cancer.org/cancer/kidneycancer/detailedguide/kidney-cancer-adult-treating-general-info|accessdate=10 September 2016}}</ref>

|1613||Development||German physician [[Daniel Sennert]] publishes his text ''Practicae Medicinae'' making the first reference suggesting a tumor arising in the [[kidney]].<ref name="Immunotherapy in Metastatic Renal Cell Carcinoma">{{cite web|title=Immunotherapy in Metastatic Renal Cell Carcinoma|url=http://cancerscienceandresearch.jacobspublishers.com/images/Cancer/J_J_Cancer_Sci_Res_1_2_012.pdf}}</ref>||

|1810||Development||Case of [[renal carcinoma]] is first described.<ref>{{cite web|title=Landmarks in the diagnosis and treatment of renal cell carcinoma|url=http://www.nature.com/nrurol/journal/v11/n9/full/nrurol.2014.194.html?message-global=remove|accessdate=6 September 2016}}</ref>||[[France]]

|1877||Development||German [[surgeon]] [[Carl Langenbuch]] performs the first [[nephrectomy]] (kidney removal) for neoplastic disease.<ref name="The contemporary role of surgery in kidney cancer">{{cite journal|title=The contemporary role of surgery in kidney cancer|pmc=2687804 | pmid=19478900 | volume=16 Suppl 1|year=2009|journal=Curr Oncol|pages=S8–S15 | last1 = Lattouf | first1 = JB | last2 = Trinh | first2 = QD | last3 = Saad | first3 = F | doi=10.3747/co.v16i0.410}}</ref>||

|1899||Development||German pathologist [[Max Wilms]] first describes nephroblastomas (kidney cancer in children), today also known as [[Wilms' tumor]]s.<ref>{{cite web|title=Wilms’ tumours|url=http://www.cancerresearchuk.org/about-cancer/cancers-in-general/cancer-questions/wilms-tumour|accessdate=6 September 2016}}</ref>||

|1932||Development||J. R. Hand and A. Broders first report a relationship between histological grade and cancer-specific survival in patients with [[renal cell carcinoma]], showing that patients with high grade of RCC are more likely to die and die sooner after [[diagnosis]] than those with low grade tumors.<ref>{{cite book|last1=Nuñez|first1=Kelvin R.|title=Focus on Kidney Cancer Research|page=101|url=https://books.google.com.ar/books?id=J5UW6DsXOHgC&pg=PA101&lpg=PA101&dq=%22kidney+cancer%22+%22in+1900..1945%22&source=bl&ots=qCgqPQQnqQ&sig=0L7VZQIqK_1TxOH-RxzMQwd9kwY&hl=en&sa=X&ved=0ahUKEwjJp62UoPzOAhWCiZAKHSIEAK8Q6AEIWTAJ#v=snippet&q=in%201932&f=false}}</ref>||

|1941||Development||First description of [[hypercalcemia]] in [[renal cell carcinoma]], separating into two categories: [[metastasis|metastatic]] and [[metastasis|nonmetastatic]].<ref name="Paraneoplastic Syndromes in Urologic Malignancy">{{cite journal|title=Paraneoplastic Syndromes in Urologic Malignancy: The Many Faces of Renal Cell Carcinoma|pmc=1475999 | pmid=16985675 | volume=4|year=2002|journal=Rev Urol|pages=163–70 | last1 = Palapattu | first1 = GS | last2 = Kristo | first2 = B | last3 = Rajfer | first3 = J}}</ref>||

|1956||Development||French physician [[Pierre Masson]] first describes [[tubulocystic renal cell carcinoma]] of the kidney.<ref>{{cite journal|title=Tubulocystic Renal Cell Carcinoma: A Rare Renal Tumor|journal=Journal of Kidney Cancer and VHL|doi=10.15586/jkcvhl.2014.13 | volume=1|pages=56}}</ref>||

|1957||Treatment||[[Thalidomide]] is launched to the market as a [[immunotherapy|immunomodulatory drug]]. Today it is used for treating some cancers, including kidney cancer.<ref>{{cite web|title=History of Thalidomide|url=http://www.news-medical.net/health/History-of-Thalidomide.aspx|accessdate=6 September 2016}}</ref>||[[Germany]]

|1960||Development||[[Nephrology]], the discipline that studies the kidney and its functions, is established.<ref>{{cite book|last1=Bickerstaff|first1=Linda|title=Kidney Cancer: Current and Emerging Trends in Detection and Treatment|url=https://books.google.com.ar/books?id=UIbsq7Uni_8C&pg=PA9&lpg=PA9&dq=%22kidney+cancer%22+%22in+1900..1970+%22&source=bl&ots=QUzmqKtixh&sig=VZIHp76NAjRSFluK0AswBpjx3fk&hl=en&sa=X&ved=0ahUKEwjonb_Kp_zOAhXEfZAKHedzDPE4FBDoAQhHMAc#v=onepage&q=%22kidney%20cancer%22%20%22in%201900..1970%20%22&f=false}}</ref>||

|1967||Discovery||[[Juxtaglomerular cell tumor]], a rare kidney tumor of the [[juxtaglomerular cells]], is first described.<ref name="kuroda">{{cite journal|last=Naoto Kuroda|title=Review of juxtaglomerular cell tumor with focus on pathobiological aspect|journal=Diagnostic Pathology|year=2011|pmc=3173291|pmid=21871063|doi=10.1186/1746-1596-6-80|volume=6|pages=80|display-authors=etal}}</ref>

|1978||Development||Researchers show that [[nephrectomy]] alone has a minimal effect on survival in patients with [[metastatic renal cell carcinoma]].<ref name="Role of surgery in advanced/metastatic renal cell carcinoma">{{cite journal|title=Role of surgery in advanced/metastatic renal cell carcinoma|doi=10.4103/0970-1591.65381|pmc=2938537 | pmid=20877591|volume=26|year=2010|journal=Indian J Urol|pages=167–76 | last1 = Bhat | first1 = S}}</ref>||

|1978||Discovery||[[Clear-cell sarcoma of the kidney]] is first described.<ref>{{cite journal|title=Clear Cell Sarcoma of Kidney in a Neonate|pmc=4420453 | pmid=26023506 | volume=3|year=2014|journal=J Neonatal Surg|pages=35 | last1 = SukdevJadhav | first1 = A | last2 = Jain | first2 = S | last3 = Tuteja | first3 = N | last4 = Agrawal | first4 = L}}</ref>||

|1985||Development||Researchers discover that [[immunotherapy]] with [[interleukin 2]] leads to long term tumor shrinkage in some patients with metastatic renal cell carcinoma.<ref name="Cancer progress">{{cite web|title=Cancer progress|url=http://cancerprogress.net/timeline/kidney-cancer|accessdate=7 September 2016}}</ref>||

|1990||Treatment||American physician Ralph Clayman performs the first [[Laparoscopic surgery|laparoscopic]] radical [[nephrectomy]] (LRN) for a kidney tumor.<ref name="Localized renal cell carcinoma management: an update">{{cite web|title=Localized renal cell carcinoma management: an update|url=http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1677-55382008000600002|accessdate=6 September 2016}}</ref>||  

|1990||Organization||The Kidney Cancer Association is founded. It provides patient information on the disease, its treatment, and clinical trials among other services.<ref name="Kidney Cancer Resources">{{cite web|title=Kidney Cancer Resources|url=http://www.oreilly.com/onconurse/factsheets/kidney_resources.html|accessdate=6 September 2016}}</ref>||[[Evanston, Illinois]], [[US]]  

|1992||Treatment||DFA approves [[interleukin 2]], which soon becomes standard therapy for advanced renal cell carcinoma.<ref name="Cancer progress" />||[[United States]]

|1995||Discovery||[[Renal medullary carcinoma]] (a rare type of cancer that affects the kidney) is first described.<ref name="Davis CJ">{{cite journal |doi=10.1097/00000478-199501000-00001 |pmid=7528470 |title=Renal Medullary Carcinoma the Seventh Sickle Cell Nephropathy |journal=The American Journal of Surgical Pathology |volume=19 |issue=1 |pages=1–11 |year=1995 |last1=Davis |first1=Charles J. |last2=Mostofi |first2=F. K. |last3=Sesterhenn |first3=Isabell A. }}</ref>||

|1995–1997||Treatment||[[Cryoablation]] and [[radiofrequency]] ablation are introduced as alternatives to surgery into small renal tumors.<ref name="Cancer progress" />||

|2000||Discovery||Researchers discover that combination of kidney removal and [[immunotherapy]] increases survival time by 50 percent in patients with advanced renal cancer.<ref name="Cancer progress" />||

|2000||Organization||[[Kidney Cancer UK]] is founded as a charity to support "[[kidney cancer]] patients, their carers, medical professionals and scientific researchers."<ref>{{cite web|title=Kidney Cancer UK|url=http://www.kcuk.org.uk/|accessdate=9 September 2016}}</ref>||[[United Kingdom]]

|2001||Development||The [[UCLA]] Integrated Staging System (UISS) prognostic model for [[renal cell carcinoma]] is developed.<ref>{{cite web|title=Kidney Cancer (Adult) - Renal Cell Carcinoma  + - Text Size Download Printable Version [PDF]» Early Detection, Diagnosis, and Staging TOPICS Document Topics GO » SEE A LIST » Previous Topic How is kidney cancer diagnosed? Next Topic Survival rates for kidney cancer by stage How is kidney cancer staged?|url=http://www.cancer.org/cancer/kidneycancer/detailedguide/kidney-cancer-adult-staging|accessdate=6 September 2016}}</ref>||[[Los Angeles]], [[California]], [[US]]

|2004||Treatment||First robot-assisted [[laparoscopy|laparoscopic]] [[nephrectomy|partial nephrectomy]] (ralpn) is introduced.<ref name="The contemporary role of surgery in kidney cancer" />||

|2004||Development||[[WHO]] introduces new classification of renal cell carcinoma, based on pathology and genetic abnormalities. Malignant tumors: [[clear cell renal cell carcinoma]], [[multilocular clear cell renal cell carcinoma]], [[papillary renal cell carcinoma]], [[chromophobe renal cell carcinoma]], [[carcinoma of the collecting ducts of Bellini]], [[renal medulary carcinoma]], [[xp11 translocation carcinomas]], [[carcinoma associated with neuroblastoma]], [[mucinous tubular and spindle cell carcinoma]], and renal cell carcinoma unclassified.<ref name="Immunotherapy in Metastatic Renal Cell Carcinoma" />||

|2005||Treatment||[[FDA]] approves Nexavar ([[sorafenib]]) for treating advanced kidney cancer.<ref name="Therapies for Advanced Kidney Cancer"/>||[[United States]]

|2006||Treatment||[[FDA]] approves Sutent ([[sunitinib malate]]) for kidney cancer patients because of its ability to reduce the size of tumors.<ref name="Therapies for Advanced Kidney Cancer">{{cite web|title=Therapies for Advanced Kidney Cancer|url=http://www.kidneycancer.org/knowledge/learn/therapies-for-advanced-kidney-cancer/|accessdate=6 September 2016}}</ref>||[[United States]]

|2007||Treatment||Intravenous drug [[temsirolimus]] (TEMSR) is approved for treating advanced renal cell carcinoma.<ref>{{cite journal|title=Temsirolimus in daily use: results of a prospective multicentre noninterventional study of patients with metastatic kidney cancer.|doi=10.1016/j.eururo.2013.08.055|pmid=24012472 | volume=66|journal=Eur Urol|pages=275-81 | last1 = Schrader | first1 = AJ | last2 = Seseke | first2 = S | last3 = Keil | first3 = C | last4 = Herrmann | first4 = E | last5 = Goebell | first5 = PJ | last6 = Weikert | first6 = S | last7 = Steffens | first7 = S | last8 = Bergmann | first8 = L | last9 = Roigas | first9 = J | last10 = Steiner | first10 = T}}</ref>||

|2008||Treatment||[[Oncophage]] is approved for use as a [[vaccine therapy]] against kidney cancer.<ref>{{cite web|title=Can we develop a vaccine for cancer?|url=https://www.weforum.org/agenda/2016/03/can-we-develop-a-vaccine-for-cancer/|accessdate=6 September 2016}}</ref>||[[Russia]]

|2009||Treatment||[[FDA]] approves Votrient ([[pazopanib]]) as an oral medication that interferes with angiogenesis, the growth of new blood vessels needed for solid tumors to grow. It is a [[Protein kinase inhibitor|kinase inhibitor]] indicated for the treatment of patients with advanced renal cell carcinoma.<ref name="Therapies for Advanced Kidney Cancer" /><ref>{{cite web|title=Pazopanib shows better quality-of-life in advanced kidney cancer|url=http://www.dana-farber.org/Newsroom/News-Releases/Pazopanib-shows-better-quality-of-life-in-advanced-kidney-cancer.aspx|accessdate=6 September 2016}}</ref>||[[United States]]

|2009||Treatment||[[Bevacizumab]] is approved for treating metastatic renal cell carcinoma after multiple studies confirm benefit when combining with [[interferon]].<ref name="Cancer progress" />||

|2009||Treatment||[[FDA]] approves [[everolimus]] to treat metastatic kidney cancer that has progressed after treatment with either [[sorafenib]] or [[sunitinib]].<ref>{{cite web|title=Adjuvant Everolimus for Resected Kidney Cancer|url=http://www.cancer.gov/types/kidney/research/adjuvant-everolimus|accessdate=6 September 2016}}</ref>||[[United States]]

|2012||Treatment||[[FDA]] approved Inlyta ([[axitinib]]) as a prescription medicine used to treat advanced renal cell carcinoma when one prior drug treatment for this disease has not worked.<ref name="Therapies for Advanced Kidney Cancer" />||[[United States]]

* [[Timeline of lung cancer]]

* [[Timeline of brain cancer]]

* [[Timeline of colorectal cancer]]

* [[Timeline of pancreatic cancer]]

* [[Timeline of liver cancer]]

* [[Timeline of bladder cancer]]

[[Category:Kidney cancer]]

[[Category:Health-related timelines]]